Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06382155 | Not yet recruiting | Idiopathic Short Stature

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
Sponsor:

BioMarin Pharmaceutical

Brief Summary:

The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS).

Condition or disease

Idiopathic Short Stature

Intervention/treatment

Vosoritide Injection

Human Growth Hormone

Placebo

Phase

Phase 2

Detailed Description:

Following a minimum 6 month observational period in which baseline growth is assessed, participants in the vosoritide and placebo groups will complete a minimum of 6 months of randomized treatment (maximum of 6 months of placebo treatment), followed by open-label treatment with vosoritide until they reach near-final adult height, or at least 16 years of age for females or 18 years of age for males, whichever comes later. Participants randomized to the hGH group will receive open-label hGH for a minimum of 4 years.

Study Type : Interventional
Estimated Enrollment : 100 participants
Masking : Quadruple
Primary Purpose : Treatment
Official Title : A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature
Actual Study Start Date : September 2024
Estimated Primary Completion Date : June 2026
Estimated Study Completion Date : December 2036
Arm Intervention/treatment

Experimental: Vosoritide Dose 1 - Low Dose

Vosoritide Dose 1 daily injection

Drug: Vosoritide Injection

Experimental: Vosoritide Dose 2 - Medium Dose

Vosoritide Dose 2 daily injection

Drug: Vosoritide Injection

Experimental: Vosoritide Dose 3 - High Dose

Vosoritide Dose 3 daily injection

Drug: Vosoritide Injection

Placebo Comparator: Placebo

Placebo daily injection

Drug: Placebo

Active Comparator: Human Growth Hormone

hGH daily injection

Drug: Human Growth Hormone
Ages Eligible for Study: 3 Years to 10 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Key Inclusion Criteria
  • Height assessment corresponding to a height Z-score of ≤ -2.25 SDs in reference to the general population of the same age and sex, as calculated using the Centers for Disease Control and Prevention (CDC) growth charts
  • Tanner Stage 1, at time of signing the ICF (unless too young to stage).
  • Key Exclusions
    • Known chromosomal imbalance or genetic variant causing short stature syndrome, including but not limited to Laron syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, Turner syndrome, disproportionate skeletal dysplasias, abnormal SHOX gene analysis, or Rasopathy (including Noonan syndrome)
    • Previous treatment with a growth promoting agent
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Location Details

Please Choose a site

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations